论文部分内容阅读
目的 探讨原发性肺癌 (肺癌 )并恶性胸水 (胸水 )的优化综合治疗方案。方法 将 40例肺癌随机分为 2组 :选择性支气管动脉灌注化疗药物 ,联合免疫治疗和胸穿抽净胸水再向胸腔内注入化疗药物 2 0例为观察组 ;单纯胸穿抽净胸水再向胸腔内注入化疗药物 2 0例为对照组。对 2组病例的近期疗效和生存率分别进行 χ2 检验。结果 首次治疗肺癌的总有效率观察组为 50 .0 %(1 0 / 2 0 ) ,较对照组 1 0 .0 % (2 / 2 0 )显著提高 (χ2 =7.62 ,P <0 .0 1 ) ;首次治疗胸水的有效率及 1年、2年的生存率观察组分别为 90 .0 % (1 8/ 2 0 )、75 .0 % (1 5/ 2 0 )、30 .0 % (6/ 2 0 ) ,较对照组 60 .0 % (1 2 / 2 0 )、40 .0 % (8/ 2 0 )、5 .0 % (1 / 2 0 )提高 (χ2 值分别为 4 .80、5 .0 1、4 .33 ,Ρ值均 <0 .0 5)。结论 选择性支气管动脉灌注化疗药物 ,联合免疫治疗和胸穿抽净胸水再向胸腔内注入化疗药物 ,是肺癌并胸水的优化综合治疗方案
Objective To investigate the optimal treatment of primary lung cancer (lung cancer) and malignant hydrothorax (pleural effusion). Methods Forty cases of lung cancer were randomly divided into two groups: selective bronchial arterial infusion of chemotherapeutic agents, combination of immunotherapy and pleural effusion with pleural effusion and intrathoracic injection of chemotherapeutic drugs 20 cases as observation group; Thoracic injection of chemotherapy drugs 20 cases for the control group. The short-term curative effect and survival rate of two groups of patients were respectively tested byχ2 test. Results The total effective rate of the first treatment of lung cancer in the observation group was 50.0% (10/20), which was significantly higher than that of the control group (2/20) (χ2 = 7.62, P <0.01 ). The effective rate of the first treatment of pleural effusion and the 1-year and 2-year survival rates in the observation group were 90.0% (18/20), 75.0% (1.5 / 20) and 30.0% (2/2 0), 40.0% (8/20) and 5. 0% (1/2 0) in the control group (χ2 = 4, respectively). 80,5. 0 1,4 .33, all P <0. 05). Conclusions Selective bronchial arterial infusion of chemotherapy drugs, combined with immunotherapy and pleural effusion through chest pleural effusion into the chest into the chemotherapy drugs, is the optimal combination of lung cancer and pleural effusion